These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 27062908)
1. Using containerless methods to develop amorphous pharmaceuticals. Weber JKR; Benmore CJ; Suthar KJ; Tamalonis AJ; Alderman OLG; Sendelbach S; Kondev V; Yarger J; Rey CA; Byrn SR Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt B):3686-3692. PubMed ID: 27062908 [TBL] [Abstract][Full Text] [Related]
2. Combination of acoustic levitation with small angle scattering techniques and synchrotron radiation circular dichroism. Application to the study of protein solutions. Cristiglio V; Grillo I; Fomina M; Wien F; Shalaev E; Novikov A; Brassamin S; Réfrégiers M; Pérez J; Hennet L Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt B):3693-3699. PubMed ID: 27155578 [TBL] [Abstract][Full Text] [Related]
3. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980 [TBL] [Abstract][Full Text] [Related]
4. A critical review of spray-dried amorphous pharmaceuticals: Synthesis, analysis and application. Wang B; Liu F; Xiang J; He Y; Zhang Z; Cheng Z; Liu W; Tan S Int J Pharm; 2021 Feb; 594():120165. PubMed ID: 33309835 [TBL] [Abstract][Full Text] [Related]
5. Emerging trends in the stabilization of amorphous drugs. Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230 [TBL] [Abstract][Full Text] [Related]
6. Refining stability and dissolution rate of amorphous drug formulations. Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747 [TBL] [Abstract][Full Text] [Related]
7. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574 [TBL] [Abstract][Full Text] [Related]
8. Nanoamorphous drug products - Design and development. Jog R; Burgess DJ Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685 [TBL] [Abstract][Full Text] [Related]
9. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying. Tian Y; Caron V; Jones DS; Healy AM; Andrews GP J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445 [TBL] [Abstract][Full Text] [Related]
10. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Caron V; Tajber L; Corrigan OI; Healy AM Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367 [TBL] [Abstract][Full Text] [Related]
11. Structural characterization and aging of glassy pharmaceuticals made using acoustic levitation. Benmore CJ; Weber JK; Tailor AN; Cherry BR; Yarger JL; Mou Q; Weber W; Neuefeind J; Byrn SR J Pharm Sci; 2013 Apr; 102(4):1290-300. PubMed ID: 23381910 [TBL] [Abstract][Full Text] [Related]
12. What is the true solubility advantage for amorphous pharmaceuticals? Hancock BC; Parks M Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982 [TBL] [Abstract][Full Text] [Related]
13. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Blagden N; de Matas M; Gavan PT; York P Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252 [TBL] [Abstract][Full Text] [Related]
14. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods. Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963 [TBL] [Abstract][Full Text] [Related]
15. [Progress in the research of amorphous pharmaceuticals]. Ying J; Lü Y; Du GH Yao Xue Xue Bao; 2009 May; 44(5):443-8. PubMed ID: 19618716 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the crystalline and amorphous states of drug products by nanothermal analysis and Raman imaging. Nakamoto K; Urasaki T; Hondo S; Murahashi N; Yonemochi E; Terada K J Pharm Biomed Anal; 2013 Mar; 75():105-11. PubMed ID: 23246930 [TBL] [Abstract][Full Text] [Related]
17. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms. Kawakami K; Usui T; Hattori M J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946 [TBL] [Abstract][Full Text] [Related]
18. Molecular structure of ketoprofen-polyvinylpyrrolidone solid dispersions prepared by different amorphization methods. Wilke SK; Benmore CJ; Menon V; Smith D; Byrn SR; Weber R RSC Pharm; 2024 Apr; 1(1):121-131. PubMed ID: 38646594 [TBL] [Abstract][Full Text] [Related]
19. Solid state amorphization of pharmaceuticals. Willart JF; Descamps M Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076 [TBL] [Abstract][Full Text] [Related]
20. Acoustic levitation: recent developments and emerging opportunities in biomaterials research. Weber RJ; Benmore CJ; Tumber SK; Tailor AN; Rey CA; Taylor LS; Byrn SR Eur Biophys J; 2012 Apr; 41(4):397-403. PubMed ID: 22038123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]